Oncology · Surgical CareTrial Updateclinicalmid-term

Trial on Targeted Temperature Management to Reduce Delirium in Cancer Surgery Patients

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:03:49 AM

Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This trial explores a novel approach to enhance postoperative care in surgical oncology, potentially improving patient outcomes and survival rates. If successful, it could lead to significant changes in clinical protocols and competitive positioning in the oncology market. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 25 ranked evidence items (7 high-relevance).

Strategic Assessment

The strongest clinical anchor is Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Surgical Care, 5 regulatory and 4 competitive items passed relevance filtering for older cancer surgery patients. Successful implementation of targeted temperature management could improve patient outcomes, thereby enhancing the reputation and market share of institutions adopting these protocols.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit. If successful, this approach could enhance postoperative care protocols, impacting surgical oncology practices and patient outcomes.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The trial's outcomes may not directly influence regulatory approvals but could inform best practices in surgical care.

Key Opportunities

Successful implementation of targeted temperature management could improve patient outcomes, thereby enhancing the reputation and market share of institutions adopting these protocols.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · Immunotherapy · Trial Update · If durvalumab demonstrates a significant survival benefit, it could position AstraZeneca favorably against competitors in the NSCLC immunotherapy space.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for statistical significance in reducing postoperative delirium and any impact on cancer recurrence rates.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Ongoing | Cancer Accelerated Approvals would change the regulatory/clinical read.
Outcome from Withdrawn | Cancer Accelerated Approvals would change the regulatory/clinical read.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cachexia and Gut Microbiota in Patients With Breast Cancer Receiving Home Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, Feasibility, and Outcomes of Early Rehabilitation After Breast Cancer Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival
Humanexa Signalsmedium relevance
Moderate corpus alignment

Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Folate receptor-targeted PEGylated PLGA nanoparticles for the site-specific delivery of hesperidin in epithelial ovarian cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Warm intranasal saline irrigation reduces intraoperative blood loss during functional endoscopic sinus surgery: a propensity score-matched cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

older cancer surgery patients
surgical oncology practices

Commercial impact

medium

Successful implementation of targeted temperature management could improve patient outcomes, thereby enhancing the reputation and market share of institutions adopting these protocols.

Regulatory impact

low

The trial's outcomes may not directly influence regulatory approvals but could inform best practices in surgical care.

What to watch

Monitor trial results for statistical significance in reducing postoperative delirium and any impact on cancer recurrence rates.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.